HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ.
Di Leo A, et al. Among authors: rouas g.
Ann Oncol. 2001 Aug;12(8):1081-9. doi: 10.1023/a:1011669223035.
Ann Oncol. 2001.
PMID: 11583189
Free article.
Clinical Trial.